Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 19/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | CCR2 | P41597 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4973495 | 0.84 | CCR5 (0.57) | CCR5CYP2D6KCNH2 | |
| SCHEMBL5503283 | 0.82 | CCR5 (0.55) | CCR5CYP2D6KCNH2CCR2 | |
| SCHEMBL3303563 | 0.81 | CCR5 (0.59) | CCR5CYP2D6KCNH2 | |
| SCHEMBL4977781 | 0.79 | CCR2 (0.46) | CCR5CCR2 | |
| SCHEMBL5238997 | 0.77 | CCR5 (0.58) | CCR5CYP2D6KCNH2CCR2 | |
| SCHEMBL4977798 | 0.76 | CCR5 (0.48) | CCR5CYP2D6KCNH2 | |
| SCHEMBL5502263 | 0.76 | CCR5 (0.48) | CCR5CYP2D6KCNH2 | |
| SCHEMBL5220283 | 0.76 | CCR5 (0.61) | CCR5CYP2D6KCNH2CCR2 | |
| SCHEMBL5235987 | 0.76 | CCR5 (0.61) | CCR5CYP2D6KCNH2CCR2 | |
| SCHEMBL5498416 | 0.75 | CCR5 (0.55) | CCR5CYP2D6KCNH2CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080021038-A1 | Novel Piperidine/8-Azabicyclo [3.2.1.] Octan Derivatives As Modulators Of Chemokine Receptor Ccr5 | TUCKER HOWARD | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021038-A1 | Novel Piperidine/8-Azabicyclo [3.2.1.] Octan Derivatives As Modulators Of Chemokine Receptor Ccr5 | CCR5, CXCR1, CCR2 | CCR5 1/4885CYP2D6 1565/4885KCNH2 1730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.